NEOVACS
Nous développons les thérapies de demain et investissons dans des sociétés innovantes en Biotech et Medtech
Nous développons les thérapies de demain et investissons dans des sociétés innovantes en Biotech et Medtech
NEOVACS is a French biotechnology company founded in 1993, with a slogan that translates to "We develop the therapies of tomorrow and invest in innovative companies in Biotech and Medtech." Specializing in the development of therapeutic vaccines for autoimmune and inflammatory diseases, NEOVACS also has a keen interest in investing in Biotech and Medtech ventures. The company's headquarters are located in France. In its most recent investment round, NEOVACS secured a €4.00M post-IPO debt investment on 22 June 2021, while the identity of the investors is undisclosed. NEOVACS is a promising player in the biotechnology and healthcare sectors, offering potential for high growth and innovation in the industry.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Post-IPO Debt | €4.00M | - | 22 Jun 2021 | |
| Post-IPO Debt | €1.00M | 1 |
|
08 Feb 2021 |
| Post-IPO Equity | €6.00M | - | 31 Jul 2017 | |
| Post-IPO Equity | €5.00M | 1 |
|
06 Jan 2016 |
| Post-IPO Equity | €7.50M | - | 29 Jun 2015 |
No recent news or press coverage available for NEOVACS.
We care about your data, and we'd love to use cookies make your experience better.
